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Abstract
Background: Proteins that are required for anchorage-independent survival of tumor cells represent attractive targets for
therapeutic intervention since this property is believed to be critical for survival of tumor cells displaced from their natural
niches. Anchorage-independent survival is induced by growth factor receptor hyperactivation in many cell types. We aimed
to identify molecules that critically regulate IGF-1-induced anchorage-independent survival.
Methods and Results: We conducted a high-throughput siRNA screen and identified PTK6 as a critical component of IGF-1
receptor (IGF-1R)-induced anchorage-independent survival of mammary epithelial cells. PTK6 downregulation induces
apoptosis of breast and ovarian cancer cells deprived of matrix attachment, whereas its overexpression enhances survival.
Reverse-phase protein arrays and subsequent analyses revealed that PTK6 forms a complex with IGF-1R and the adaptor
protein IRS-1, and modulates anchorage-independent survival by regulating IGF-1R expression and phosphorylation. PTK6 is
highly expressed not only in the previously reported Her2
+ breast cancer subtype, but also in high grade ER
+, Luminal B
tumors and high expression is associated with adverse outcomes.
Conclusions: These findings highlight PTK6 as a critical regulator of anchorage-independent survival of breast and ovarian
tumor cells via modulation of IGF-1 receptor signaling, thus supporting PTK6 as a potential therapeutic target for multiple
tumor types. The combined genomic and proteomic approaches in this report provide an effective strategy for identifying
oncogenes and their mechanism of action.
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Introduction
Adhesion to extracellular matrix (ECM) provides epithelial cells
with critical cues about their environment that are required for
their proliferation, survival and tissue organization. Loss of
attachment to matrix compromises viability of normal epithelial
cells through a variety of mechanisms that help preserve tissue
homeostasis and prevent aberrant growth (reviewed in [1], [2]).
Detachment from matrix triggers apoptosis, termed anoikis, via
both intrinsic and extrinsic death pathways. However, most tumor
cells have acquired the ability to resist anoikis and this property is
believed to be critical for tumor cell dissemination and survival in
altered matrix environments [1], [2]. Genes that have been
demonstrated to suppress anoikis also promote metastases in vivo,
further supporting a critical role for anoikis regulation in
tumorigenesis [3], [4].
Tumor cells adopt several different strategies to evade anoikis
including: (1) activation of survival pathways such as those
regulated by Erk/MAPK and Akt through oncogenic mutations
or constitutive growth factor receptor activation; (2) modulation
of expression or activity of anti-apoptotic and pro-apoptotic
proteins including Bcl2 family members, and (3) altered
expression and engagement of integrins by basement membrane
proteins produced via autocrine mechanisms (reviewed in [1],
[2]). Large-scale cDNA screens have identified several candidate
genes that when overexpressed either alone or in combination
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11729with other oncogenes suppress anoikis through any or all of these
mechanisms [4].
As a complement to these gain-of-function screens, loss-of-
function screens also provide insight into mechanisms that are
necessary for anoikis suppression and identify potential targets for
therapeutic intervention. Screens utilizing small molecule inhibi-
tors have previously been reported [5], [6]; these studies have
highlighted multiple ways in which anoikis resistance may be
overcome, including manipulation of the extrinsic cell death
pathway and hypoosmotic stress. Here we present a novel siRNA
screen designed to identify regulators of IGF-1 receptor (IGF-1R)-
driven anoikis resistance of breast epithelial cells.
IGF-1R has been shown to be expressed in the majority of
human breast cancers with evidence of sporadic amplification in a
small proportion of these cases [7], [8]. Although initially thought
to correlate with estrogen receptor (ER) expression, IGF-1R has
recently been implicated in multiple breast cancer subtypes and its
expression correlates with poor prognoses [9], [10]. IGF-1
stimulation directly induces anoikis resistance of several different
epithelial cell types (including breast, prostate, and colon) by
activating downstream signaling molecules such as Ras/MAPK
and PI3K/Akt [11]. IGF-1R is also required for transformation
and anoikis suppression induced by other oncogenes, such as Ras,
c-Src, SV40 Large T antigen and the chimeric ETV6-NTRK3
(reviewed in [12], [13]). Based on these findings, we utilized
mammary epithelial cells expressing elevated levels of IGF-1R for
a siRNA screen to identify mediators of anoikis protection. In
addition, use of cells in which a known gene drives protection from
anoikis greatly facilitates mechanistic follow-up studies. This
siRNA screen led to the identification of PTK6, a member of
the Src family of tyrosine kinases that is frequently overexpressed
in a variety of tumor types [14–17]. Here we demonstrate a critical
role for PTK6 in anchorage-independent survival of specific
subtypes of breast cancer cells. We also present evidence for IGF-1
receptor regulation as a novel mechanism for survival regulation
by PTK6.
Results
Loss-of-function screen to identify genes involved in
anchorage-independent survival induced by IGF-1R
stimulation
In contrast to non-transformed MCF-10A mammary epithelial
cells, MCF-10A cells overexpressing IGF-1 receptor (IGF-1R cells)
exhibit enhanced survival in suspension cultures with IGF-1
stimulation (Figure 1A). To identify genes that are required for
Figure 1. siRNA screen identifies regulators of IGF-1-induced anchorage-independent survival. A) IGF-1R hyperstimulation enhances
anchorage-independent survival of MCF-10A cells. MCF-10A cells overexpressing vector control or IGF-1R (IGF-1R) were cultured on adherent plates
or in suspension cultures for 48 hours. The cells were collected and cell death was assessed by measuring cytoplasmic histone and DNA content in
triplicate wells (Roche Diagnostics). Higher values indicate more death. The fold change is the average of three independent experiments. Error bars
indicate standard deviation. Western blot analysis shows relative IGF-1R levels in the cell lines. B) Candidate siRNAs that are critical for IGF-1R-induced
anchorage-independent survival were identified by a loss-of-function screen. In the primary screen, a library of siRNA oligonucleotides targeting all
human kinases was screened using the IGF1R overexpressing MCF10A line. Alamar blue reduction was assayed. Positives from the primary screen
were counter-screened in MCF10A cells cultured in 2% Matrigel in suspension. The screen positives that showed a differential effect in IGF1R-
overexpressing cells compared to the MCF10A cells in Matrigel were selected for validation using additional sequences.
doi:10.1371/journal.pone.0011729.g001
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were transfected in suspension cultures with a library of individual
siRNA oligonucleotides targeting all human kinases and related
proteins (Figure 1B). The ability of individual siRNAs to modulate
or reverse IGF-1dependent survival was initially assessed by
monitoring changes in Alamar Blue reduction signal. Candidate
siRNAs identified in the primary screen were rescreened using
parental MCF-10A cells cultured in suspension with reconstituted
basement membrane proteins to prioritize those siRNAs that more
specifically inhibited IGF-1 driven survival. Lastly we screened
additional siRNAs targeting the IGF-1R specific hits to identify
those genes that were targeted by three or more distinct siRNA
sequences.
PTK6 modulates IGF-1 dependent anoikis resistance
PTK6 was identified as a ‘‘high-confidence’’ candidate gene
because multiple siRNA oligonucleotides caused a significant,
preferential inhibition of IGF-1R-driven anchorage-independent
viability when compared to parental MCF-10A cells. PTK6 was
also considered an attractive candidate for further study because it
is highly expressed in multiple tumor types, including breast and
ovarian tumors [14–16], [18]. Low level expression of PTK6
protein was detected in parental MCF-10A cells grown in
suspension cultures; this expression was enhanced in IGF-1R cells
(Figure S1A) All three oligonucleotides identified in the phenotypic
screen downregulated PTK6 protein expression effectively, as did
a pool of siRNA olgonucleotides (OTP) from an independent
vendor (Figure S1B). We also identified a lentivirally-delivered
shRNA vector that effectively downregulated PTK6 protein
expression (Figure 2A, left).
To more specifically determine whether PTK6 downregulation
induces cell death of IGF-1R cells in suspension cultures, we
utilized Cell Death ELISA assays and monitored cleavage of
PARP, a caspase target. Downregulating PTK6 by either
transfecting siRNA oligonucleotides or expressing an shRNA
vector enhanced death of IGF-1R cells in suspension with
enhanced detection of cleaved PARP product (Figure 2A and
Figure S1C). The effect of PTK6 downregulation on apoptosis is
specific for matrix-deprived cells as downregulation of PTK6 had
no effect on attached IGF-1R cells (Figure 2A), supporting the
specificity of the screen in identifying genes that modulate survival
only in matrix-detached conditions. This death was inhibited by
ZVAD-fmk, a pan-caspase inhibitor, further supporting a role for
PTK6 in suppressing anoikis induced by matrix detachment
(Figure 2A).
Downregulation of PTK6 inhibits luminal filling induced
by IGF-1R hyperstimulation
Acquisition of anchorage-independent survival is believed to
play a role in the abnormal accumulation of cells in the lumen of
terminal breast acinar structures, a property that is commonly
observed in human breast lesions like ductal carcinoma in situ
(DCIS). Consistent with this, we have found that filling of the
matrix-free lumen of mammary acinar structures in 3D culture
models requires induction of both hyperproliferation and anti-
apoptotic activity [19].
We and others have previously reported that IGF-1R
hyperstimulation of breast epithelial cells results in the formation
of abnormally large structures with filled lumen due to
hyperproliferation and suppression of death of the centrally
localized cells in the presumptive luminal space [20], [21]. To
address whether PTK6 plays a critical role in modulating the
survival of cells in the luminal space, we examined the effects of
PTK6 downregulation on IGF-1-induced acinar formation and
luminal filling. PTK6 shRNA expression in IGF-IR/MCF-10A
cells suppressed the formation of large, hyperproliferative
structures (Figure 2B left). While many PTK6 shRNA-expressing
structures resembled parental MCF-10A acini, some were aborted
in early stages of outgrowth. These results indicate that PTK6 is
also critical for IGF-1R-induced hyperproliferation in 3D culture.
In contrast, downregulation of PTK6 had no significant effect on
basal morphogenesis of parental MCF-10A cells (Figure 2B left).
We then examined the effect of PTK6 downregulation on IGF-
1R-induced luminal filling in 3D cultures. Compared to acini
expressing vector control, PTK6 downregulation resulted in a
significantly higher percentage of structures with clear lumen
(Figure 2B right). Thus, PTK6 is critical for anchorage-
independent survival of cells in suspension and in the luminal
space of IGF-1R overexpressing acinar structures. The combined
effects of PTK6 downregulation on proliferation and anchorage-
independent survival contribute to inhibition of abnormal acinar
formation induced by IGF-1R stimulation.
Overexpression of PTK6 enhances anchorage-
independent survival
To complement the loss-of-function studies, we examined the
effect of overexpressing PTK6 in both MCF-10A cells and
immortalized human mammary epithelial cells (HMLE). Overex-
pression of PTK6 in parental MCF-10A cells using either a
FLAG-tagged wild type PTK6 (F-PTK6) or myristylated,
membrane targeted PTK6 (MF-PTK6), was sufficient for a
modest, but significant, suppression of cell death upon detachment
from matrix (Figure 3A). MCF-10A cells overexpressing MF-
PTK6 consistently displayed a greater degree of anoikis resistance
when compared to cells overexpressing F-PTK6. PTK6 kinase
activity is important for suppression of anoikis of MCF-10A cells,
as overexpression of a kinase-inactive MF-PTK6 (KD-MFPTK6)
did not significantly rescue these cells from matrix detachment-
induced cell death (Figure 3B).
Overexpression of PTK6 alone (MF-PTK6 or F-PTK6) in
HMLE was not sufficient to significantly promote colony
formation in soft agar, another measure of anchorage-independent
survival (Figure S2). However, PTK6 was able to enhance soft
agar colony growth induced by other oncogenes that activate the
PI3-K or Erk pathways (Figure 3C). Utilizing a cell system similar
to that described previously in which activated Akt and MEK are
used to substitute for Ras activation in transformation of
immortalized HMEC [22], we observed that overexpression of
PTK6 in immortalized HMLE expressing either activated MEK
(HMLE-M) or myristylated Akt (HMLE-A) significantly enhanced
colony formation (Figure 3B). Interestingly, membrane-targeted
PTK6 was as effective, if not more effective, than wild type PTK6
in enhancing colony formation. Although PTK6 lacks a native
myristylation sequence (in contrast to other Src family kinases),
PTK6 has been reported to localize to membrane ruffles and
associate with membrane-bound receptors such as EGFR and
ErbB2 [23–25]. Membrane-localization may therefore play a
critical role in the collaborative transforming functions of PTK6.
PTK6 modulates anoikis sensitivity of breast and ovarian
cancer cells expressing IGF-1R
We sought to determine whether PTK6 plays a critical role in
modulating anchorage-independent survival of breast and ovarian
cancer cells in which PTK6 is highly expressed, particularly those
which co-express IGF-1R. Examination of a panel of cell lines
revealed that PTK6 was abundantly expressed in several Her2
+
breast cancer lines, as previously reported (Figure S3A). Down-
PTK6 Regulates Survival
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11729Figure 2. PTK6 downregulation reverses IGF-1-induced anchorage-independent survival. A) An shRNA vector targeting PTK6 reverses
IGF-1R-induced anchorage-independent survival. (Left) Western analysis confirmed downregulation of PTK6 expression and demonstrated increased
PARP cleavage with PTK6 downregulation in IGF-1R cells in suspension cultures. (Middle) IGF-1R cells expressing control or PTK6 shRNA vector were
cultured as attached cells or in suspension cultures in the presence of IGF-1. Cell death was assessed after 48 hours as in Figure 1. The average fold
change from three independent experiments is shown. Error bars indicate standard deviation. (Right) PTK6 regulates apoptosis of matrix-detached
IGF-1R cells. IGF-1-stimulated IGF-1R cells expressing control or PTK6 shRNA vector were grown in suspension cultures for 48 hours in the presence or
absence of ZVAD-fmk (25 mM). Cell death was assessed as in Figure 1. The average fold change from three independent experiments is shown. Error
bars indicate standard deviation. B) PTK6 downregulation inhibits morphological changes induced by IGF-1R hyperstimulation. (Left) IGF-1R or
parental MCF-10A cells expressing control or PTK6shRNA vector were grown in 3D Matrigel
TM cultures for 8 days. Representative phase contrast
images are shown. Scale bar indicates 100mm. (Right) PTK6 downregulation inhibits IGF-1R-induced luminal filling. IGF-1R or parental MCF-10A cells
expressing control or PTK6 shRNA vector were grown in 3D
TM Matrigel cutures for 8 days and stained with anti-laminin 5 (LAMC2) antibody (red) and
DAPI (blue). Representative confocal images are shown. Cells in the central lumen were counted and acinar structures were classified as ‘‘clear’’ (no
cells in the lumen), ‘‘mostly clear’’ (,5 cells in the lumen) or ‘‘filled’’ (.5 cells in the lumen). The average distribution from three independent
experiments is shown. Error bars indicate standard deviation. Scale bar indicates 50 mm.
doi:10.1371/journal.pone.0011729.g002
PTK6 Regulates Survival
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11729regulation of PTK6 was associated with increased anoikis of
BT474 cells and ErbB2 overexpressing MCF-10A cells (NeuN),
lines in which anchorage-independent survival is induced via the
ErbB2 growth factor receptor, supporting a role for PTK6 in
survival of Her2
+ cells (Figures 4A and 4B). PTK6 was also highly
expressed in several Her2
2,E R
+ cell lines, including MCF-7
(Figure S3A). MCF-7 cells express high levels of endogenous IGF-
1R, thereby providing another context for evaluating the role of
PTK6 in IGF-1 induced, anchorage-independent survival. Stim-
ulation of MCF-7 cells with IGF-1 rescued cells from anoikis,
which was significantly reversed by downregulation of PTK6
(Figure 4C). This death was inhibited by the caspase inhibitor
ZVAD-fmk, again supporting a role for PTK6 in modulating
apoptosis of breast cancer cells under matrix-detached conditions.
These results support an expanded role for PTK6 in growth factor
receptor-induced anoikis resistance of breast cancer cells.
Downregulation of PTK6 also prevented IGF-1 stimulated
anoikis resistance of DOV-13 ovarian cancer cells, which co-
express PTK6 and IGF-1R (Figure 4D). There is increasing
evidence supporting a role for IGF-1 signaling in ovarian tumor
progression [26], [27]. Furthermore, PTK6 has previously been
reported to be amplified and overexpressed in a significant
number of ovarian cancers although its functions in ovarian
tumorigenesis have not been studied [18]. In contrast to normal
human ovarian surface epithelial (HOSE) cells which do not
express detectable levels of PTK6, DOV-13 cells express higher
levels of PTK6 protein ([18] and Figure S3B). While DOV-13
cells are relatively sensitive to anoikis when compared to HOSE
cells, IGF-1 stimulation enhances survival in suspension
(Figure 4D). Downregulation of PTK6 reverses this IGF-1
induced anchorage-independent survival. Interestingly downreg-
ulation of PTK6 also enhanced basal levels of death, suggesting
that it may also play a critical role in anchorage-independent
survival of DOV-13 cells distinct from its role in IGF-1-
stimulated anoikis resistance.
Regulation of IGF-1R signaling by PTK6
To begin to elucidate the mechanisms by which PTK6
modulates anchorage-independent survival, we utilized reverse-
phase protein arrays (RPPA) to identify signaling molecules that
are altered by downregulation or overexpression of PTK6
(Figures 5A, 6A). IGF-1R cells overexpressing Bcl2 (IGF/Bcl2)
were transfected with multiple different siRNA oligonucleotides
targeting PTK6 in suspension cultures in order to minimize
changes in phosphoprotein signatures resulting secondarily from
apoptosis. Decreased expression of PTK6 was associated with
Figure 3. Effects of PTK6 overexpression on anchorage-independent survival. A) Overexpression of PTK6 enhances anchorage-
independent survival. MCF-10A cells overexpressing vector control or FLAG-tagged PTK6, with or without a myristylation sequence (MF-PTK6 or F-
PTK6, respectively), were cultured in suspension for 48 hours. Cell death was assessed as in Figure 1. The average of three independent experiments
is shown. Error bars indicate standard deviation. Western blot analysis shows relative expression levels of PTK6 for each cell line. B) Overexpression of
kinase inactive PTK6 does not rescue MCF-10A cells from anoikis. MCF-10A cells overexpressing vector control, MF-PTK6 or a kinase inactive PTK6 (KD-
MFPTK6) were cultured in suspension for 48 hours. Cell death was assessed as in Figure 1. The average of three independent experiments is shown.
Error bars indicate standard deviation. Relative expression and activity of PTK6 in each cell line was assessed by Western blot analyses. C)
Overexpression of PTK6 enhances soft agar growth in collaboration with other oncogenes. HMLE cells expressing MEK
DD (HMLE-M) or myristylated
Akt (HMLE-A) were engineered to express vector control, F-PTK6 or MF-PTK6. Soft agar colony growth was assessed after four weeks. A representative
experiment of three replicate experiments using triplicate wells for each cell line is shown. Error bars indicate standard deviation. Western blot
analysis shows levels of expression of PTK6 in each cell line.
doi:10.1371/journal.pone.0011729.g003
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growth factor signaling pathways. Downregulation of PTK6
induced an increase in metabolic ‘‘stress’’ as indicated by the
enhanced signal intensities for AMPK and phospho-AMPK, and
its substrate phospho-ACC. In contrast, there was a decrease in
the signal intensities for phospho-Akt, phospho-Erk and phospho-
Figure 4. PTK6 downregulation inhibits anchorage-independent survival of breast and ovarian cancer cells. A) PTK6 downregulation
inhibits survival of Her2
+ cells. The effect of PTK6 downregulation on anchorage-independent survival of MCF-10A cells overexpressing ErbB2 was
assessed. Cell death was assessed as in Figure 1. The average fold change in cell death from three independent experiments is shown. Error bars
indicate standard deviation. B) PTK6 downregulation inhibits survival of Her2+ breast cancer cells. The effect of downregulating PTK6 on anchorage-
independent survival of BT474 cells was assessed. Cell death was assessed as in Figure 1. The average fold change in cell death from three
independent experiments is shown. Error bars indicatestandard deviation. C) Downregulation of PTK6 inhibits IGF-1-induced survival of MCF-7 breast
cancer cells. The effect of PTK6 downregulation on anchorage-independent survival of IGF-1 (100ng/ml) stimulated MCF-7 breast cancer cell line was
assessed in the presence or absence of ZVAD-fmk (25mM). Cell death was assessed as in Figure 1. The average fold change in cell death from three
independent experiments is shown. Error bars indicate standard deviation. D) Downregulation of PTK6 inhibits IGF-1 induced survival of DOV-13
ovarian cancer cells. The effect of PTK6 downregulation on anchorage-independent survival of DOV-13 ovarian cancer cells was determined in the
presence or absence of IGF-1 (100ng/ml). Cell death was assessed as in Figure 1. The average fold change in cell death from three independent
experiments is shown. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0011729.g004
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signaling pathways, either as a primary or secondary consequence.
Interestingly, we observed that the signal intensities for phospho-
IGF-1R and total IGF-1R were also decreased on the protein
array, which raised the possibility that PTK6 modulates activation
and/or expression of the receptor itself, thereby influencing
multiple downstream signaling molecules. Western analyses of
lysates derived from IGF-1 stimulated MCF-7 cells confirmed that
downregulation of PTK6 resulted in decreased levels of IGF-1
receptor phosphorylation of known autophosphorylation sites
(tyrosine 1131, 1135 and 1136) which are required for maximal
IGF-1R kinase activity (Figure 5B). This decrease in IGF-1R
phosphorylation was not associated with a decrease in IGF-1R
levels. The effects of PTK6 downregulation on IGF-1 receptor
phosphorylation are unlikely to be secondary to changes in
viability induced by matrix deprivation as these changes were
observed in IGF-1R cells co-expressing Bcl2 which are protected
from anoikis induced by PTK6 downregulation. Furthermore,
similar changes in IGF-1 receptor phosphorylation were observed
with downregulation of PTK6 in attached DOV-13 ovarian
cancer cells (Figure 5C). PTK6 downregulation-induced decreases
in signaling downstream of IGF-1R (e.g. Akt, Erk) were also
confirmed in MCF-7 cells acutely stimulated with IGF-1 in
suspension cultures (Figure 5D).
The effect of overexpressing PTK6 on IGF-1R phosphorylation
was also examined (Figure 6). In the RPPA studies an enhanced
signal for phospho-IGF-1R (phosphorylated at tyrosine 1131/
1135/1136) was detected with overexpression of active, PTK6
Figure 5. PTK6 downregulation affects IGF-1 dependent signaling pathways. A) Reverse-phase protein arrays (RPPA) reveal changes in IGF-
1-stimulated signaling with PTK6 downregulation. RPPA analysis was performed on lysates of IGF-1R cells overexpressing Bcl2 (IGF-1R/Bcl2) that were
transfected with control or PTK6 siRNA oligonucleotides in suspension cultures containing IGF-1 (100ng/ml). The heatmap represents values
normalized to luciferase control from transfections performed in triplicate. B) shRNA-mediated downregulation of PTK6 in MCF-7 cells decreases
ligand-stimulated IGF-1R phosphorylation. MCF-7 cells expressing control or PTK6 shRNA were stimulated in suspension cultures for the indicated
times with 100ng/ml IGF-1. Lysates were probed with the indicated antisera. C) DOV-13 cells cultured on adherent plates were stimulated with
100ng/ml IGF-1 for 20 minutes. Lysates were probed with the indicated antisera. D) PTK6 downregulation inhibits IGF-1- stimulated activation of Akt
and Erk/MAPK. Lysates of MCF-7 cells stimulated with the indicated concentrations of IGF-1 for 60 minutes (left panel) or 15 minutes (right panel) in
suspension cultures were probed with the indicated antisera.
doi:10.1371/journal.pone.0011729.g005
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phosphorylation was observed in MCF-10A cells overexpressing
a catalytically active, membrane-targeted PTK6 (MF-PTK6)
(Figure 6A). Increased levels of total IGF-1R accompanied the
enhanced phosphorylation, whereas downregulation of PTK6
affected phosphorylation independent of receptor levels. Overex-
pression of kinase-inactive PTK6 (KD-MFPTK6) also slightly
enhanced IGFR phosphorylation, although not to the level
observed with MF-PTK6. No change in total receptor level was
observed with overexpression of KD-MFPTK6. PTK6 overex-
pression does not have a general effect on membrane-associated
receptor tyrosine kinases in suspension, as levels of EGFR,
previously reported to activate PTK6, were unchanged
(Figure 6B). Moreover, the enhanced IGF-1R phosphorylation is
unlikely to be simply secondary to enhanced viability of MCF-10A
cells in suspension cultures as overexpression of Akt, which
potently inhibits anoikis, did not result in similar changes in IGF-
1R levels or phosphorylation (Figure 6B).
Previous studies have shown that PTK6 is able to form
complexes with EGF receptor family members and PTK6 couples
these receptors to downstream signaling pathways [28]. PTK6
could also regulate IGF-1R signaling by physical association with
the receptor complex, as PTK6 was previously shown to associate
with IRS-4 in HEK-293 cells [29]. In MCF-10A cells overex-
pressing IGF-1R and PTK6, PTK6 co-precipitated with IGF-1R
(Figure 6C). PTK6 was also detected in immune complexes
containing IRS-1, suggesting that PTK6 may regulate IGF-1R by
associating with the receptor:adapter complex.
To determine whether IGF-1R kinase activity is critical for the
suppression of anoikis induced by PTK6 overexpression, we
assessed the effect of BMS-536924, an IGF-1R/insulin receptor
inhibitor, on the anchorage-independent survival of MCF-10A
cells overexpressing MF-PTK6. Cells were cultured in suspension
in the presence of sub-saturating doses of the inhibitor, which
reversed the enhanced survival induced by PTK6 (Figure 6D and
Figure S4). Collectively, these results provide evidence for PTK6’s
Figure 6. Overexpression of PTK6 enhances anchorage-independent survival by regulating IGF-1R phosphorylation. A) PTK6
overexpression increases phosphorylation of IGF-1R. (Left) MCF-10A cells overexpressing a constitutively active (CA) or kinase-inactive (KD) PTK6 were
grown in suspension cultures for 48 hours in the presence of IGF-1 (100ng/ml). Lysates were prepared and probed using RPPA. The values represent
the average normalized expression values derived from triplicate samples. Error bars indicate standard deviation. (Right) Lysates prepared from
suspension cultures of MCF-10A cells overexpressing vector control, MF-PTK6 or kinase-inactive MF-PTK6 (KD-MFPTK6) were probed with the
indicated antisera. B) Lysates prepared from suspension cultures of MCF-10A cells overexpressing vector control, MF-PTK6 or wild type Akt in the
presence of IGF-1 (100ng/ml) were probed with the indicated antisera. C) PTK6 co-precipitates with IGF-1R and IRS-1 adapter protein. Lysates of MCF-
10A cells overexpressing IGF-1R and wild type PTK6 were immunoprecipitated with the indicated antisera and immunoblotted with anti-PTK6
antibody. D) Anchorage-independent survival stimulated by PTK6 overexpression is suppressed by IGF-1R kinase inhibition. MCF-10A cells
overexpressing vector control or MF-PTK6 were grown in suspension cultures containing IGF-1 (100ng/ml) for 48 hours in the absence or presence of
BMS-536924 at the indicated concentrations. Cell death was assessed as described in Figure 1. The fold change in cell death represents the average of
three independent experiments. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0011729.g006
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and IGF-1 stimulated signaling.
PTK6 is amplified and expressed in specific subtypes of
human breast tumors
PTK6 may promote human cancer growth by modulating
signaling via growth factors receptors, such as IGF-1R and ErbB2.
PTK6 has been reported to be expressed in multiple tumor types,
including breast and ovarian cancer [14–16], [18]. This expression
pattern may be in part due to copy number gain as PTK6 maps to
Chromosome 20q13.3, a region frequently amplified in breast
tumors. Recently, Xiang et al. reported coamplification of PTK6
in Her2
+ breast tumors [23]. We examined PTK6 copy number in
a cohort of 93 breast tumors. Genomic DNA extracted from a
series of breast tumors was hybridized to SNP (Single Nucleotide
Polymorphism) arrays [30] (Figure 7A). PTK6 copy number gain
(copy number greater than or equal to 3.0) was observed in 15 of
93 breast tumors (15%) in SNP analysis. Most PTK6 copy number
gains are modest and with the exception of one tumor, are broad
(,2.8Mbp) gains (Figure S5). Fluorescence in situ hybridization of
tumors selected on the basis of elevated PTK6 signal intensity in
microarray analyses showed an increase in the number of
hybridized signals with the PTK6-specific probe (Figure 7B). For
some tumor cells within a sample, there was also an observed
increase in the number of hybridized signals with the Chromo-
some 20 centromere-specific probe, suggesting that in some cases
apparent PTK6 copy number gains may be due to increased
numbers of chromosome 20. A statistically significant correlation
Figure 7. PTK6 copy number gain and overexpression in primary human breast tumor samples. A) (Top) SNP array analyses of 93 breast
tumors demonstrates PTK6 copy number gain in a subet of tumors.The x-axis represents individual breast tumor specimens; the y-axis represents
copy number. The red line indicates copy number=3 (Bottom) Correlation analysis with other amplified genes is shown. The table lists the number of
tumors with PTK6 copy number gain (copy number$3.0), the Pearson product-moment correlation for each pair of variables and the associated P-
values. B) FISH analysis demonstrates PTK6 copy number gain. Two human breast tumors were selected for FISH analyses based on high PTK6
transcript expression levels in microarray analyses. FISH analysis was performed using a probe specific for PTK6 (green) or a control chromosome 20
centromeric probe (pink). C) PTK6 mRNA is differentially expressed in human breast cancer subtypes. Publicly available datasets were used to
compare levels of PTK6 mRNA in breast cancer subtypes (basal, HER2/ERBB2
+, Luminal A, Luminal B) and normal samples. P-values were calculated
using ANOVA in JMP 7.0 software. D) PTK6 mRNA level is a predictor of prognosis in human breast cancer. Kaplan-Meier curves depict the probability
of breast cancer recurrence based on relative levels of PTK6 transcript expression. Probabilities for the entire cohort (top) as well as the ER
+ subgroup
(bottom) were determined. The Cox regression test evaluates the association of PTK6 level with patient outcome treating the level of PTK6 as a
continuous variable. The log-rank test evaluates whether there are significant differences between any of the three groups. Data sets from Van’t Veer
et al. (Van’t Veer et al., 2002) and Wang et al.(Wang et al., 2005) were analyzed.
doi:10.1371/journal.pone.0011729.g007
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also observed (Figure 7A). However, in contrast to a previous
report [23], a correlation with ErbB2 amplification was not
observed in the set of tumors analyzed for this study.
We examined the relative expression of PTK6 mRNA in
different breast tumor subtypes (Figure 7C). In previously
published microarray analyses of breast tumor specimens
downloaded from Oncomine, PTK6 transcript levels were
elevated in nearly all breast tumor subtypes with the exception
of basal-like tumors. PTK6 expression was the highest in both
Her2
+ and high-grade ER
+ (Luminal B) tumors. Many Luminal B
tumors also express high levels of IGF-1R transcript (data not
shown).
Elevated levels of PTK6 mRNA expression are associated with
prognostic significance. In two large breast cancer patient cohorts
with long-term follow up, tumor specimens were stratified based
on PTK6 expression levels. Patients with tumors with the highest
expression levels of PTK6 mRNA transcript in each cohort were
less likely to be recurrence-free over long-term follow up
(Figure 7D, top). This prognostic significance was observed
independent of estrogen receptor or nodal status in multivariate
analyses (data not shown). High PTK6 transcript levels were also
associated with adverse outcomes for the subset of patients with
ER
+ tumors in both cohorts (Figure 7D, bottom). This prognostic
significance was observed in multiple other cohorts that utilized
different array platforms (Figure S6).
Discussion
In contrast to normal epithelial cells, most cancer cells have
acquired the ability to grow in an anchorage-independent manner.
In this report, we identified PTK6 as a gene that is critically
involved in IGF-1R-stimulated anchorage-independent survival
using a highly validated siRNA screen. PTK6 was also found to be
required for anchorage independence of breast and ovarian cancer
cells. These findings were supported by gain-of-function studies
showing that PTK6 is an effective ‘‘collaborative oncogene’’,
efficiently enhancing transformation in combination with other
activated oncogenes. Insights into the mechanisms whereby PTK6
induces anoikis resistance were provided by high throughput
protein arrays and subsequent analyses, which demonstrated that
loss of PTK6 had broad effects on the major signaling pathways
activated by IGF-1R as well as IGF-1R itself. Subsequent studies
confirmed that PTK6 regulates the expression and the activity of
IGF-1R. Effects of PTK6 on anchorage-independence could
contribute to the poor outcomes associated with high PTK6
transcript levels that we found in multiple cohorts of breast cancer
patients.
Our studies indicate that PTK6 regulates anchorage-indepen-
dent survival through suppression of caspase-mediated apoptosis,
as downregulation of PTK6 increased PARP cleavage and resulted
in cell death that was inhibited by ZVAD-fmk. Interestingly,
Harvey et al. recently reported that downregulation of PTK6 in
the matrix-deprived T47-D breast cancer cells induces autophagy,
but not apoptosis [31]; however, they did not assess whether
autophagy was responsible for cell death. Matrix detachment has
been shown to cause metabolic impairment [32] and induce
autophagy associated with activation of AMPK, an enzyme that
senses metabolic stress [33]. Interestingly, inhibition of autophagy
enhances apoptotic cell death in MCF-10A cells [33], suggesting
that autophagy promotes epithelial cell survival, rather than cell
death, in matrix-detached MCF-10A cells.
RPPA analyses in this study demonstrated that AMPK and its
target protein ACC were activated by PTK6 downregulation,
indicating that loss of PTK6 also causes metabolic stress. In
addition, although cell death induced by PTK6 downregulation
was inhibited by ZVAD-fmk, the metabolic impairment was not
(data not shown). While autophagy can be an adaptive survival
mechanism for cells under stress it can also progress to cell death
(reviewed in [34], [35]). It is possible that both autophagy and
apoptosis play roles in cell death resulting from PTK6 downreg-
ulation and the relative contribution may differ depending on
cellular context, levels of anti-apoptotic proteins and duration of
matrix deprivation. Our studies together with previous reports
[36], [37] indicating that PTK6 may regulate multiple signaling
molecules infer that there may be multiple mechanisms by which
PTK6 regulates cell growth and survival.
Overexpression of PTK6 enhanced anchorage-independent
survival. Although PTK6 is distantly related to the Src family of
tyrosine kinases with an SH3, SH2 and catalytic domain, it lacks a
native myristylation signal shared by most members of this class
[14], [38]. The ability of myristylated PTK6 to effectively enhance
anchorage-independent survival points to a potentially critical role
for membrane localization in this oncogenic function of PTK6.
During the preparation of this manuscript, Kim and Lee also
reported that myristylated PTK6, but not nuclear localized PTK6,
promoted proliferation, migration, and colony formation of
HEK293 cells [39]. Membrane localization is not a general
requirement for all src-family kinases, as a related kinase Frk,
which also lacks a native myristylation sequence, failed to enhance
soft agar colony growth when targeted to the membrane
(unpublished data). Thus subcellular localization likely determines
access to specific substrates and interacting partners that modulate
PTK6’s role in tumorigenesis.
While the ability of PTK6 to enhance signaling downstream of
EGF receptor family kinases is well established [24], [28], our
studies are the first to highlight the ability of PTK6 to regulate
other growth factor receptor kinases, namely IGF-1R. Comple-
mentary protein arrays performed on cells with either overex-
pression or downregulation of PTK6 revealed an effect of PTK6
on IGF-1 receptor phosphorylation and function. This ability of
PTK6 could underpin its critical role in a subset of breast tumors
which do not express substantial levels of ErbB receptor family
kinases, but rather express high levels of both IGF-1R and PTK6.
Specifically, we observed a trend for high- grade ER
+ (i.e. Luminal
B) tumors to express high levels of both of these transcripts (data
not shown); therefore, PTK6 may contribute to the growth and
survival of these tumors by modulating IGF-1R signaling.
Whether the effects of PTK6 on IGF-1R function involve direct
interactions with the receptor remain to be addressed. The ability
of PTK6 to regulate the IGF-1 receptor does not appear to be
dependent on a secreted factor as conditioned media from cells in
which PTK6 expression was modulated failed to induce any
change in IGF-1R (data not shown). The ability of PTK6 to co-
precipitate with both the IGF-1 receptor and IRS-1 suggests that
PTK6 is able to associate with the receptor complex. Interestingly,
v-Src has been reported to directly phosphorylate the beta chain of
the IGF-1 receptor at the corresponding autophosphorylation sites
in rat fibroblasts with subsequent activation of IGF-1R kinase, and
IGF-1R is required for v-Src transforming activity [40]. PTK6, a
Src family member, may similarly phosphorylate IGF-1R directly
following recruitment to the membrane.
Although both gain- and loss-of-function approaches used in
this report highlighted a positive role for PTK6 in anchorage-
independent survival, other studies utilizing mouse intestinal cells
and rat fibroblasts suggest that PTK6 may be required for cell
death triggered by specific stimuli such as DNA damage [41], [42].
There may be tissue-specific functions of PTK6 depending on
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given the critical role that subcellular localization may play in
oncogenic vs. non-oncogenic activity, the ability of PTK6 to be
recruited to the membrane by any mechanism may determine its
ultimate role in cell survival.
PTK6 is expressed in multiple human tumor types, including
breast and ovarian tumors [14–16,18]. PTK6 maps to a
chromosomal region (20q13.3) that is frequently amplified in
breast tumors and amplicons spanning this region variably contain
other suspected oncogenes, such as TDE1, NCoA3, BCAS4, and
ZNF217. The PTK6 copy number gain detected in our study is
relatively modest. However, it is possible that low levels are
sufficient to contribute to tumorigenic phenotypes collaboratively,
as we have shown that PTK6 effectively collaborates with other
oncogenic signaling pathways. In multiple microarray studies,
elevated PTK6 mRNA expression was most highly associated with
specific breast cancer subtypes (Her2
+ and Luminal B/high grade
ER
+). Although we have shown that PTK6 expression is critical
for anchorage-independent survival of representative cell lines of
these subtypes, the full range of functions attributable to PTK6
expression in these specific subtypes (e.g. regulation of sensitivity to
chemotherapy or endocrine therapy, proliferation) remains to be
addressed.
In our study we analyzed the prognostic significance of elevated
PTK6 transcript expression in multiple large cohorts of patients
with breast cancer. Our finding that elevated expression of PTK6
transcript correlates with adverse outcomes for patients with breast
cancer in all cohorts analyzed is consistent with a recently reported
correlation between PTK6 mRNA levels and tumor grade based
on analyses of 44 tumors [31]. However, this association of PTK6
with adverse outcome contrasts with findings of another group
who reported (1) no correlation between PTK6 mRNA expression
levels and disease-free survival, and (2) a positive correlation
between PTK6 protein expression (determined by immunohisto-
chemistry) and long-term disease-free survival. [43–45]. The exact
basis for this discrepancy with our findings for PTK6 mRNA levels
is not clear, although the analyses of Aubele et al. were all
performed on a single cohort. Their finding with respect to PTK6
protein expression is intriguing; the lack of correlation between
immunohistochemical signal intensity and either PTK6 FISH
signals or transcript levels suggests that PTK6 protein levels may
be regulated post-transcriptionally. Further complicating the
studies of prognostic significance is the finding that subcellular
localization of PTK6 protein may critically regulate oncogenic
activity; in studies of prostate tumor cells, cytoplasmic localization
of PTK6, in contrast to nuclear expression, was associated with
poor differentiation and androgen independence, which are
adverse prognostic factors [46]. Thus, immunohistochemical
analyses of breast tumor specimens with attention to PTK6
expression in specific subcellular compartments could be infor-
mative.
PTK6 is an attractive potential therapeutic target for breast and
ovarian cancer for several reasons. The rather restricted
expression of PTK6 in normal tissues and the prevalence of
PTK6 copy number gain and high expression in some breast and
ovarian tumors improve the chance of selectively targeting
malignant cells. PTK6 overexpression could contribute to
resistance to currently available therapies, such as those targeting
Her2 amplified tumors [23]. Inhibition or downregulation of
PTK6 may also prove to be an effective strategy for enhancing the
response of high-grade ER
+/Luminal B breast cancers to
endocrine therapy or overcoming acquired resistance to these
agents. Validation of PTK6 as a viable target will depend on
identifying those tumors in which PTK6 is functionally active and
determining the specific substrates and domains of PTK6 that are
required for its oncogenic activity.
Materials and Methods
Reagents, cells and cell culture
MCF-10A, ZR751, MCF-7, BT474, DOV-13, Hey C2 and
human immortalized mammary epithelial cells (HMEC) were
obtained from ATCC (Manassas, Virginia). MCF-10A cells
overexpressing IGF-1R receptor (IGF-1R) have been previously
described [21]. MCF-10A cells and IGF-1R cells were cultured, as
previously described [21], [47]. ZR-751 cells were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum. MCF-7
cells were cultured in DMEM supplemented with 10% FBS.
Ovarian cancer lines were cultured in RPMI-0 supplemented with
10% fetal bovine serum and penicillin/streptomycin. Three-
dimensional (3D) Matrigel
TM cultures were performed as
described previously [21]. ZVAD-fmk, a pan-caspase inhibitor,
was purchased from BD Biosciences. IGF-1 receptor kinase
inhibitor (BMS-536924) was purchased from Selleck and solubi-
lized in DMSO. Antiserum or monoclonal antibodies directed
against the following proteins were obtained from the indicated
suppliers: Cell Signaling Technologies: phospho-IGF-1R (tyrosine
1131/1135/1136), phospho-Akt (Ser 473), Akt, cleaved PARP,
phospho-STAT3, EGFR and Akt1; Santa Cruz Biotechnology:
IGF-1R, PTK6, Erk2, tubulin; Biosource: phospho-Erk1/2;
Millipore: IRS-1 and phospho-Brk; and Chemicon: Laminin
5,c2 subunit (LAMC2). Alamar Blue was purchased from
Biosource.
Constructs, virus production and stable cell line
generation
The constructs for PTK6 (kinase-active and kinase-inactive)
were generated by cloning into pMSCV-puro. The construct
encoding short hairpin RNA sequences targeting PTK6 was
obtained from Open Biosystems (Catalog # TRCN0000021552).
pBP-MF-PTK6 and pBP-F-PTK6 were obtained from the
Harvard Institute of Proteomics (gift of Haley Hieronymus and
Jesse Boehm). Viral packaging 293T or GPG-293T cells were
transfected according to standard protocols. Viral supernatant was
collected 36 and 60 hrs post-transfection. Immortalized HMECs
or MCF-10A cells were infected in the presence of 2mg/ml
polybrene with the viral supernatant or were spin-infected for
30 minutes at 2250 rpm. After three hours, media was changed on
the target cells, which were then allowed to recover overnight,
followed by another round of infection. Forty-eight hours post-
infection, the target cells were exposed to puromycin (0.5–1 mg/ml
for 48 hrs) to select for infected cells.
Anchorage-independent viability screen
A library consisting of two individual siRNA sequences targeting
human kinases were obtained from Qiagen (v.1.0). MCF-10A cells
overexpressing IGF-1R were trypsinized and plated in 96 well
plates pre-coated with polyhema (Sigma). Cells were transfected
using Oligofectamine in quadruplicate wells with individual
siRNA duplexes from the Qiagen kinase siRNA library. Cells
were cultured for an additional 72 hours in suspension and
assayed for Alamar reducing potential on a multiplate reader
according to the manufacturer’s protocol.
In the counter screen, parental MCF-10A cells cultured on
polyhema plates were transfected with siRNA duplexes. After four
hours the media was supplemented with Matrigel
TM to a final
concentration of 2%. After an additional 72 hour incubation,
Alamar blue reduction was assayed as above. The ratio between
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for MCF10A cells grown in Matrigel was calculated. This ratio
was used to select candidates for testing additional siRNA
reagents.
Assessment of cell death
Cell death in suspension cultures was assessed using the Cell
Death ELISA kit (Roche Diagnostics).according to the manufac-
turer’s instructions.
Soft agar colony assays
The bottom layer of soft agar contained 0.6% agar with DMEM
and 5% serum. Fifteen thousand cells were seeded per well on the
top layer that contained 0.3% agar in MEGM. Cells were seeded
in triplicate wells of six-well plates. Wells were re-fed every two
weeks and colonies were counted at four weeks post-plating. At
each time point, an image of each well was taken at 66
magnification and processed using the software Image J. Colonies
larger than 50 sq. pixels were counted.
SNP array analysis
Breast tumors for SNP array analysis were collected from de-
identified cases using protocol #98-229 approved by the Institutional
Review Board of the Dana-Farber Cancer Institute. SNP array
analyses were performed by the Dana-Farber Microarray Core and
by the Broad Institute using Affymetrix 250K StyI arrays, according
to methods described by Nikolsky et al [30]. The raw .CEL files were
normalized and copy number of each SNP was determined using the
GenePattern software [30]. Raw SNP copy numbers were smoothed
by a segmentation algorithm using the DNA copy package (available
at www.bioconductor.org). Copy numbers of each gene were
estimated by averaging copy numbers from all SNPs found within
the gene structure and flanking 100-kbp regions. All of the raw data
were deposited into Oncomine and Gene Expression Omnibus
(GSE19399) and are publicly available: (https://www.oncomine.
com/resource/login.html and http://www.ncbi.nlm.nih.gov/sites/
entrez?db=gds&term=GSE19399[Accession]&cmd=search).
FISH analysis of tumors
A fosmid probe specific for PTK6 and a Chromosome 20
centromere probe were obtained from CHORI/BacPac library.
Hybridization and analyses were performed by the Dana-Farber/
Harvard Cancer Center Cytogenetics Core Facility (P30
CA006516).
Microarray analyses
Breast tumor subtype analyses. Boxplots showing the level
of PTK6 mRNA in breast tumor subtypes were derived from three
data sets: (1) GSE1992 downloaded from the Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/projects/geo/)
[48], (2) Rosetta Inpharmatics (http://www.rii.com/
publications/2002/vantveer.html) [49] and (3) a gene expression
array (Affymetrix U133) of 129 sporadic primary invasive breast
tumors which includes tumors published previously [50], [51].
Boxplots were generated in Matlab and p-values (ANOVA) were
calculated in JMP 7.0. Classification of tumors in the Van’t Veer
data set was obtained from GEO (GSE4382) [52].
For GSE5460, raw expression values obtained from Affymetrix
GENECHIP software were additionally analyzed using DNA-
Chip analyzer (dChip) custom software (www.dchip.org). Parallel
data of 12 normal breast organoids RNA samples and 7 bulk
normal breast tissue specimens were used as normal control. Array
probe data were normalized to the mean probe expression level
across the cohort; thus, expression levels are relative to a
normalized average. Gene filtering and hierarchical cluster
analysis were performed using dChip software to identify subtypes
of breast tumors using the intrinsic gene list defined by Sorlie et al.
[52]. Two PTK6 probes in the array 206482_at and
1553114_a_at were used for analysis of PTK6 transcripts level.
The relative levels of hybridization for the two probes were highly
correlated (linear regression R=0.83).
Kaplan-Meier curves. For the Van’t Veer data set,
normalized PTK6 expression values and time to recurrence data
were downloaded from the Rosetta website (http://www.rii.com/
publications/2002/vantveer.html). Samples were divided into
three equal tertiles: 98 tumors with highest PTK6 level
(.0.053); 99 tumors with intermediate PTK6 level (between
20.021 and 0.056) and 98 tumors with lowest PTK6 level
(,20.021). For the ER
+ plots, only the 226 samples classified as
ER+ by Van’t Veer et al. were used.
For the Wang set, PTK6 expression values and time to
recurrence data were downloaded from the Gene Expression
Omnibus (GEO, GSE2034). Samples were divided into three equal
tertiles: 95 tumors with highest PTK6 level (.242.3); 96 tumors
with intermediate PTK6 level (between 126.3 and 243.7) and 95
tumors with lowest PTK6 level (,126.9). For the ER
+ plots, only
the 209 samples classified as ER+ by Wang et al. were used.
For all survival curves, the y-axis (probability) is defined as the
frequency of relapse-free survival. Kaplan-Meier analyses were
carried out using survival package within R language. P-values
were derived using the log-rank test and by fitting a Cox
proportional hazards regression model. Multivariate Cox propor-
tional hazards analysis was performed for PTK6 and clinical
prognostic factors including estrogen receptor (ER),HER2 onco-
gene, axillary lymph node involvement.
Immunoprecipitations, and Western analyses
Cells were lysed in RIPA lysis buffer (1%Triton X-100,
1%NaDOC, 0.1%SDS, 20mM Tris pH 7.5, 150 mM NaCl,
1mM EDTA) or RPPA lysis buffer (1% Triton X-100, 50mM
HEPES, 150mM NaCl, 1.5mM MgCl2, 1mM EDTA, 100mM
NaF, 10mM NaPP, 10% glycerol, 1mM PMSF, 1mM Na3V04)
supplemented with protease and phosphatase inhibitors (1mg/ml
leupeptin, 1 mg/ml aprotinin, 1 mg/ml pepstatin, 10 mg/ml
PMSF, 1 mM NaVO4, 1mM NaF) for 30 minutes at 4uC. Lysates
were clarified by centrifugation and supernatants were collected.
Proteins were resolved by 8–10% SDS-PAGE gel electrophoresis
and immunoblotted using standard techniques.
Reverse phase protein array (RPPA) analysis
Serially diluted cell lysates were printed on nitrocellulose-coated
slides and probed with specific antibodies as previously reported
[53]. Signal intensity data were collected and analyzed using
software specifically developed for RPPA analyses (http://www.
vigenetech.com). The normalized linear values for each sample
were divided by the trimmed mean (25%) of the values for that
sample. Each value was standardized using a modified z-score.
Z~
median of replicates{median of luciferase replicates
s
Heatmaps were generated using Cluster 3.0 and Java TreeView
1.1.1.
Phase contrast microscopy
Cells grown in monolayer cultures, as well as 3D acinar
structures were visualized at 20uC using a Nikon TE300
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objective. Images were acquired using ImageJ software, converted
to TIFF images and arranged using Adobe Photoshop 7.0.
Immunofluorescence analyses and confocal microscopy
Acinar structures were fixed in 2% formalin (Sigma) at room
temperature for 20 minutes and permeabilized in 0.5% Triton X-
100 in PBS for 10 min at 4uC. Immunostaining of acinar
structures was carried out as previously described [47] and imaged
at 20uC. DAPI was purchased from Molecular Probes. Confocal
analyses were performed using the Nikon TE2000 microscope
with the C1plus confocal microscope system equipped with
krypton-argon (488 line) and HeNe (543 and 633 lines) lasers.
Structures were analyzed with a 406/1.3 objective and images
were acquired using the Nikon C1 Confocal software. All images
were converted to TIFF format and arranged using Adobe
Photoshop 7.0.
Supporting Information
Figure S1 siRNAs targeting PTK6 identified by the screen
inhibit anchorage-independent survival of IGF-1R cells. A)
Parental and IGF-1R overexpressing MCF-10A cells transfected
with control or PTK6 siRNA (OTP, Dharmacon) were cultured in
suspension for 48 hours. Lysates were probed with the indicated
anti-sera. B) Western analysis demonstrates down regulation of
PTK6 expression in IGF-1R cells by siRNAs targeting PTK6
identified by the screen to induce changes in viability. IGF-1R cells
transfected with multiple PTK6 siRNAs, including a pool of
siRNAs from a distinct vendor (OTP, Dharmacon), were cultured
in suspension for 48 hours. Lysates were prepared and probed
with the indicated anti-sera. C) siRNAs targeting PTK6 inhibit
anchorage-independent survival of IGF-1R cells. IGF-1R cells
transfected with multiple PTK6 siRNAs, including a pool of
siRNAs from a distinct vendor (OTP, Dharmacon), were cultured
in suspension for 48 hours. Cell death was assessed as described in
Figure 1. The average fold change from three independent
experiments is shown. Error bars indicate standard deviation.
Found at: doi:10.1371/journal.pone.0011729.s001 (0.24 MB TIF)
Figure S2 Overexpression of PTK6 alone in HMEC does not
enhance growth in soft agar. Immortalized human mammary
epithelial cells (HMLE) overexpressing vector control, F-PTK6 or
MF-PTK6, were seeded in soft-agar, and colony formation was
assessed after four weeks. A representative experiment of three
replicate experiments using triplicate wells for each cell line is shown.
Found at: doi:10.1371/journal.pone.0011729.s002 (0.08 MB TIF)
Figure S3 Expression of PTK6 in breast and ovarian cancer cell
lines. A) Western blot analysis was performed to assess levels of
PTK6 protein expression in a panel of breast cancer cell lines
representative of different subtypes, as classified in Neve et al. [54].
B) Western blot analyses were performed to assess levels of PTK6
expression in human ovarian surface epithelial cells and ovarian
cancer cell lines.
Found at: doi:10.1371/journal.pone.0011729.s003 (0.53 MB TIF)
Figure S4 Effect of IGF-1R kinase inhibitor on IGF-1R
signaling. IGF-1R overexpressing MCF-10A cells were treated in
suspension cultures containing IGF-1 (100ng/ml) for 48 hours
with the indicated concentrations of IGF-1 receptor kinase
inhibitor (BMS-536924; Selleck). Lysates were probed with the
indicated antisera to assess IGF-1R autophosphorylation and
phosphorylation of Akt.
Found at: doi:10.1371/journal.pone.0011729.s004 (0.28 MB TIF)
Figure S5 Cluster analysis of chromosome 20 copy number
alterations in breast cancers. The heatmap is based on SNP array
copy number data from 93 breast tumor samples with 511
chromosome 20 genes (ordered from p arm to q arm). Only data
above log2 value 0.5 or below 20.5 were used (representing copy
numbers above 2.8 or below 1.4). Left, cluster of the entire
chromosome 20; right, magnification of the yellow box. Dark blue,
red, and light blue colors represent losses, gains, and no significant
change in copy number.
Found at: doi:10.1371/journal.pone.0011729.s005 (1.07 MB TIF)
Figure S6 Higher levels of PTK6 mRNA are associated with
clinical measures of poor prognosis in multiple breast cancer data
sets. Box plots and data are from the Oncomine database (www.
oncomine.org). Background corrected expression data are log2
transformed and the median value per microarray is scaled to zero
by subtracting the median from each value. The standard
deviation of values for each microarray is scaled to 1. P-values
are derived from the Student’s t-test.
Found at: doi:10.1371/journal.pone.0011729.s006 (0.65 MB TIF)
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